@article{WiegeringRiegelWagneretal.2017, author = {Wiegering, Armin and Riegel, Johannes and Wagner, Johanna and Kunzmann, Volker and Baur, Johannes and Walles, Thorsten and Dietz, Ulrich and Loeb, Stefan and Germer, Christoph-Thomas and Steger, Ulrich and Klein, Ingo}, title = {The impact of pulmonary metastasectomy in patients with previously resected colorectal cancer liver metastases}, series = {PLoS ONE}, volume = {12}, journal = {PLoS ONE}, number = {3}, doi = {10.1371/journal.pone.0173933}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-158036}, pages = {e0173933}, year = {2017}, abstract = {Background 40-50\% of patients with colorectal cancer (CRC) will develop liver metastases (CRLM) during the course of the disease. One third of these patients will additionally develop pulmonary metastases. Methods 137 consecutive patients with CRLM, were analyzed regarding survival data, clinical, histological data and treatment. Results were stratified according to the occurrence of pulmonary metastases and metastases resection. Results 39\% of all patients with liver resection due to CRLM developed additional lung metastases. 44\% of these patients underwent subsequent pulmonary resection. Patients undergoing pulmonary metastasectomy showed a significantly better five-year survival compared to patients not qualified for curative resection (5-year survival 71.2\% vs. 28.0\%; p = 0.001). Interestingly, the 5-year survival of these patients was even superior to all patients with CRLM, who did not develop pulmonary metastases (77.5\% vs. 63.5\%; p = 0.015). Patients, whose pulmonary metastases were not resected, were more likely to redevelop liver metastases (50.0\% vs 78.6\%; p = 0.034). However, the rate of distant metastases did not differ between both groups (54.5 vs.53.6; p = 0.945). Conclusion The occurrence of colorectal lung metastases after curative liver resection does not impact patient survival if pulmonary metastasectomy is feasible. Those patients clearly benefit from repeated resections of the liver and the lung metastases.}, language = {en} } @article{WiegeringPfannUtheetal.2013, author = {Wiegering, Armin and Pfann, Christina and Uthe, Friedrich Wilhelm and Otto, Christoph and Rycak, Lukas and M{\"a}der, Uwe and Gasser, Martin and Waaga-Gasser, Anna-Maria and Eilers, Martin and Germer, Christoph-Thomas}, title = {CIP2A Influences Survival in Colon Cancer and Is Critical for Maintaining Myc Expression}, series = {PLoS ONE}, journal = {PLoS ONE}, doi = {10.1371/journal.pone.0075292}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-97252}, year = {2013}, abstract = {The cancerous inhibitor of protein phosphatase 2A (CIP2A) is an oncogenic factor that stabilises the c-Myc protein. CIP2A is overexpressed in several tumours, and expression levels are an independent marker for long-term outcome. To determine whether CIP2A expression is elevated in colon cancer and whether it might serve as a prognostic marker for survival, we analysed CIP2A mRNA expression by real-time PCR in 104 colon cancer samples. CIP2A mRNA was overexpressed in colon cancer samples and CIP2A expression levels correlated significantly with tumour stage. We found that CIP2A serves as an independent prognostic marker for disease-free and overall survival. Further, we investigated CIP2A-dependent effects on levels of c-Myc, Akt and on cell proliferation in three colon cancer cell lines by silencing CIP2A using small interfering (si) and short hairpin (sh) RNAs. Depletion of CIP2A substantially inhibited growth of colon cell lines and reduced c-Myc levels without affecting expression or function of the upstream regulatory kinase, Akt. Expression of CIP2A was found to be dependent on MAPK activity, linking elevated c-Myc expression to deregulated signal transduction in colon cancer.}, language = {en} } @article{WangChenMinevetal.2012, author = {Wang, Huiqiang and Chen, Nanhai G. and Minev, Boris R. and Szalay, Aladar A.}, title = {Oncolytic vaccinia virus GLV-1h68 strain shows enhanced replication in human breast cancer stem-like cells in comparison to breast cancer cells}, series = {Journal of Translational Medicine}, volume = {10}, journal = {Journal of Translational Medicine}, number = {167}, doi = {10.1186/1479-5876-10-167}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-130019}, year = {2012}, abstract = {Background: Recent data suggest that cancer stem cells (CSCs) play an important role in cancer, as these cells possess enhanced tumor-forming capabilities and are responsible for relapses after apparently curative therapies have been undertaken. Hence, novel cancer therapies will be needed to test for both tumor regression and CSC targeting. The use of oncolytic vaccinia virus (VACV) represents an attractive anti-tumor approach and is currently under evaluation in clinical trials. The purpose of this study was to demonstrate whether VACV does kill CSCs that are resistant to irradiation and chemotherapy. Methods: Cancer stem-like cells were identified and separated from the human breast cancer cell line GI-101A by virtue of increased aldehyde dehydrogenase 1 (ALDH1) activity as assessed by the ALDEFLUOR assay and cancer stem cell-like features such as chemo-resistance, irradiation-resistance and tumor-initiating were confirmed in cell culture and in animal models. VACV treatments were applied to both ALDEFLUOR-positive cells in cell culture and in xenograft tumors derived from these cells. Moreover, we identified and isolated CD44\(^+\)CD24\(^+\)ESA\(^+\) cells from GI-101A upon an epithelial-mesenchymal transition (EMT). These cells were similarly characterized both in cell culture and in animal models. Results: We demonstrated for the first time that the oncolytic VACV GLV-1h68 strain replicated more efficiently in cells with higher ALDH1 activity that possessed stem cell-like features than in cells with lower ALDH1 activity. GLV-1h68 selectively colonized and eventually eradicated xenograft tumors originating from cells with higher ALDH1 activity. Furthermore, GLV-1h68 also showed preferential replication in CD44\(^+\)CD24\(^+\)ESA\(^+\) cells derived from GI-101A upon an EMT induction as well as in xenograft tumors originating from these cells that were more tumorigenic than CD44\(^+\)CD24\(^-\)ESA\(^+\) cells. Conclusions: Taken together, our findings indicate that GLV-1h68 efficiently replicates and kills cancer stem-like cells. Thus, GLV-1h68 may become a promising agent for eradicating both primary and metastatic tumors, especially tumors harboring cancer stem-like cells that are resistant to chemo and/or radiotherapy and may be responsible for recurrence of tumors.}, language = {en} } @article{VerghoKneitzKalogirouetal.2014, author = {Vergho, Daniel Claudius and Kneitz, Susanne and Kalogirou, Charis and Burger, Maximilian and Krebs, Markus and Rosenwald, Andreas and Spahn, Martin and L{\"o}ser, Andreas and Kocot, Arkadius and Riedmiller, Hubertus and Kneitz, Burkhard}, title = {Impact of miR-21, miR-126 and miR-221 as Prognostic Factors of Clear Cell Renal Cell Carcinoma with Tumor Thrombus of the Inferior Vena Cava}, doi = {10.1371/journal.pone.0109877}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-113633}, year = {2014}, abstract = {Clear cell renal cell carcinoma (ccRCC) characterized by a tumor thrombus (TT) extending into the inferior vena cava (IVC) generally indicates poor prognosis. Nevertheless, the risk for tumor recurrence after nephrectomy and thrombectomy varies. An applicable and accurate prediction system to select ccRCC patients with TT of the IVC (ccRCC/TT) at high risk after nephrectomy is urgently needed, but has not been established up to now. To our knowledge, a possible role of microRNAs (miRs) for the development of ccRCC/TT or their impact as prognostic markers in ccRCC/TT has not been explored yet. Therefore, we analyzed the expression of the previously described onco-miRs miR-200c, miR-210, miR-126, miR-221, let-7b, miR-21, miR-143 and miR-141 in a study collective of 74 ccRCC patients. Using the expression profiles of these eight miRs we developed classification systems that accurately differentiate ccRCC from non-cancerous renal tissue and ccRCC/TT from tumors without TT. In the subgroup of 37 ccRCC/TT cases we found that miR-21, miR-126, and miR-221 predicted cancer related death (CRD) accurately and independently from other clinico-pathological features. Furthermore, a combined risk score based on the expression of miR-21, miR-126 and miR-221 was developed and showed high sensitivity and specificity to predict cancer specific survival (CSS) in ccRCC/TT. Using the combined risk score we were able to classify ccRCC/TT patients correctly into high and low risk cases. The risk stratification by the combined risk score (CRS) will benefit from further cohort validation and might have potential for clinical application as a molecular prediction system to identify high- risk ccRCC/TT patients.}, language = {en} } @article{TelesYanoVillarinhoetal.2021, author = {Teles, Ramon Handerson Gomes and Yano, Rafael Sussumu and Villarinho, Nicolas Jones and Yamagata, Ana Sayuri and Jaeger, Ruy Gastaldoni and Meybohm, Patrick and Burek, Malgorzata and Freitas, Vanessa Morais}, title = {Advances in breast cancer management and extracellular vesicle research, a bibliometric analysis}, series = {Current Oncology}, volume = {28}, journal = {Current Oncology}, number = {6}, issn = {1718-7729}, doi = {10.3390/curroncol28060382}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-284321}, pages = {4504 -- 4520}, year = {2021}, abstract = {Extracellular vesicles transport variable content and have crucial functions in cell-cell communication. The role of extracellular vesicles in cancer is a current hot topic, and no bibliometric study has ever analyzed research production regarding their role in breast cancer and indicated the trends in the field. In this way, we aimed to investigate the trends in breast cancer management involved with extracellular vesicle research. Articles were retrieved from Scopus, including all the documents published concerning breast cancer and extracellular vesicles. We analyzed authors, journals, citations, affiliations, and keywords, besides other bibliometric analyses, using R Studio version 3.6.2. and VOSviewer version 1.6.0. A total of 1151 articles were retrieved, and as the main result, our analysis revealed trending topics on biomarkers of liquid biopsy, drug delivery, chemotherapy, autophagy, and microRNA. Additionally, research related to extracellular vesicles in breast cancer has been focused on diagnosis, treatment, and mechanisms of action of breast tumor-derived vesicles. Future studies are expected to explore the role of extracellular vesicles on autophagy and microRNA, besides investigating the application of extracellular vesicles from liquid biopsies for biomarkers and drug delivery, enabling the development and validation of therapeutic strategies for specific cancers.}, language = {en} } @article{StaigerCadotKooteretal.2012, author = {Staiger, Christine and Cadot, Sidney and Kooter, Raul and Dittrich, Marcus and M{\"u}ller, Tobias and Klau, Gunnar W. and Wessels, Lodewyk F. A.}, title = {A Critical Evaluation of Network and Pathway-Based Classifiers for Outcome Prediction in Breast Cancer}, series = {PLoS One}, volume = {7}, journal = {PLoS One}, number = {4}, doi = {10.1371/journal.pone.0034796}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-131323}, pages = {e34796}, year = {2012}, abstract = {Recently, several classifiers that combine primary tumor data, like gene expression data, and secondary data sources, such as protein-protein interaction networks, have been proposed for predicting outcome in breast cancer. In these approaches, new composite features are typically constructed by aggregating the expression levels of several genes. The secondary data sources are employed to guide this aggregation. Although many studies claim that these approaches improve classification performance over single genes classifiers, the gain in performance is difficult to assess. This stems mainly from the fact that different breast cancer data sets and validation procedures are employed to assess the performance. Here we address these issues by employing a large cohort of six breast cancer data sets as benchmark set and by performing an unbiased evaluation of the classification accuracies of the different approaches. Contrary to previous claims, we find that composite feature classifiers do not outperform simple single genes classifiers. We investigate the effect of (1) the number of selected features; (2) the specific gene set from which features are selected; (3) the size of the training set and (4) the heterogeneity of the data set on the performance of composite feature and single genes classifiers. Strikingly, we find that randomization of secondary data sources, which destroys all biological information in these sources, does not result in a deterioration in performance of composite feature classifiers. Finally, we show that when a proper correction for gene set size is performed, the stability of single genes sets is similar to the stability of composite feature sets. Based on these results there is currently no reason to prefer prognostic classifiers based on composite features over single genes classifiers for predicting outcome in breast cancer.}, language = {en} } @article{SchmidtSkafGavriletal.2017, author = {Schmidt, Marianne and Skaf, Josef and Gavril, Georgiana and Polednik, Christine and Roller, Jeanette and Kessler, Michael and Holzgrabe, Ulrike}, title = {The influence of Osmunda regalis root extract on head and neck cancer cell proliferation, invasion and gene expression}, series = {BMC Complementary and Alternative Medicine}, volume = {17}, journal = {BMC Complementary and Alternative Medicine}, number = {518}, doi = {10.1186/s12906-017-2009-4}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-158704}, year = {2017}, abstract = {Background: According to only a handful of historical sources, Osmunda regalis, the royal fern, has been used already in the middle age as an anti-cancer remedy. To examine this ancient cancer cure, an ethanolic extract of the roots was prepared and analysed in vitro on its effectiveness against head and neck cancer cell lines. Methods: Proliferation inhibition was measured with the MTT assay. Invasion inhibition was tested in a spheroid-based 3-D migration assay on different extracellular matrix surfaces. Corresponding changes in gene expression were analysed by qRT-PCR array. Induction of apoptosis was measured by fluorescence activated cell sorting (FACS) with the Annexin V binding method. The plant extract was analysed by preliminary phytochemical tests, liquid chromatography/mass spectroscopy (LC-MS) and thin layer chromatography (TLC). Anti-angiogenetic activity was determined by the tube formation assay. Results: O. regalis extract revealed a growth inhibiting effect on the head and neck carcinoma cell lines HLaC78 and FaDu. The toxic effect seems to be partially modulated by p-glycoprotein, as the MDR-1 expressing HLaC79-Tax cells were less sensitive. O. regalis extract inhibited the invasion of cell lines on diverse extracellular matrix substrates significantly. Especially the dispersion of the highly motile cell line HlaC78 on laminin was almost completely abrogated. Motility inhibition on laminin was accompanied by differential gene regulation of a variety of genes involved in cell adhesion and metastasis. Furthermore, O. regalis extract triggered apoptosis in HNSCC cell lines and inhibited tube formation of endothelial cells. Preliminary phytochemical analysis proved the presence of tannins, glycosides, steroids and saponins. Liquid chromatography/mass spectroscopy (LC-MS) revealed a major peak of an unknown substance with a molecular mass of 864.15 Da, comprising about 50\% of the total extract. Thin layer chromatography identified ferulic acid to be present in the extract. Conclusion: The presented results justify the use of royal fern extracts as an anti-cancer remedy in history and imply a further analysis of ingredients.}, language = {en} } @phdthesis{Riedel2001, author = {Riedel, Walter K.}, title = {Metastasierungsverhalten von Mundh{\"o}hlenkarzinomen in Abh{\"a}ngigkeit vom Therapieregime}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-1181791}, school = {Universit{\"a}t W{\"u}rzburg}, year = {2001}, abstract = {In der vorliegenden retrospektiven Studie wurde das Metastasierungsverhalten von Mundh{\"o}hlenkarzinomen des Krankengutes der Klinik und Poliklinik f{\"u}r Mund-, Kiefer- und Gesichtschirurgie der Universit{\"a}t W{\"u}rzburg aus den Jahren 1985 bis 1999 bei unterschiedlichen Therapiekonzepten untersucht. 774 Patienten wurden in die Untersuchung einbezogen. Das Durchschnittsalter der Patienten betrug 59 Jahre. Das Verh{\"a}ltnis von m{\"a}nnlichen zu weiblichen Patienten lag bei 4:1. 36,3 Prozent (280) der Tumoren lagen im Bereich des Mundbodens, 15,9 Prozent (123) in der Unterlippe, 13,7 Prozent (106) im Bereich des Oropharynx, 12,4 Prozent (96) im Unterkiefer-Alveolarfortsatz, 10,2 Prozent (79) in der Zunge, 7,1 Prozent (55) in Oberkiefer und Gaumen, 3,1 Prozent (24) in der Wangenschleimhaut und 1,2 Prozent (9) in der Oberlippe. Eine alleinige chirurgische Tumorresektion wurde bei 60,1 Prozent (465) der Patienten durchgef{\"u}hrt. Eine chirurgische Therapie mit pr{\"a}operative Radiatio (40 Gy) erhielten 1,3 Prozent (10) der Patienten, eine chirurgische Therapie mit kombinierter pr{\"a}operativer Radio-Chemo-Therapie (40 Gy) erhielten 25,5 Prozent (197). 7,4 Prozent (57) der Patienten erhielten eine alleinige Radio-Chemo-Therapie, 4,9 Prozent (38) eine Radiatio solo. Postoperativ wurde eine Bestrahlung bei 5,0 Prozent (39) und eine Chemotherapie bei 0,3 Prozent (2) der Patienten durchgef{\"u}hrt. 21,0 Prozent (163) aller Patienten erhielten eine ipsilaterale Lymphknotenausr{\"a}umung, 22,4 Prozent (173) eine bilaterale Lymphbahnausr{\"a}umung. 50,6 Prozent (170) der Patienten, deren Halsweichteile ausger{\"a}umt wurden, erhielten ipsilateral eine radikale Neck dissection, 21,4 Prozent (72) eine konservierende Neck dissection, 28,0 Prozent (94) eine suprahyoidale Ausr{\"a}umung. 72,5 Prozent (561) der Patienten blieben innerhalb der Nachbeobachtungszeit (durchschnittlich 2,9 Jahre) rezidiv- bzw. metastasenfrei. Ein Lokalrezidiv entwickelten 14,9 Prozent (115) der Patienten. Metastasen entwickelten innerhalb der Nachbeobachtungszeit 16,5 Prozent (128) der Patienten: 68,8 Prozent (88) region{\"a}re Metastasen, 31,2 Prozent (40) Fernmetastasen. Einen statistisch signifikanten Einfluss (p<0,05) auf die Metastasenh{\"a}ufigkeit hatte die Lokalisation des Prim{\"a}rtumors (26,3 Prozent Metastasen bei Tumoren im Bereich der Wangenschleimhaut, 24,3 Prozent bei Mundbodenkarzinomen, 23,6 Prozent bei Oropharynxkarzinomen, 20,0 Prozent bei Oberkieferkarzinomen, 15,9 Prozent bei Zungenkarzinomen, 13,4 Prozent bei Karzinomen des Unterkiefer-Alveolarfortsatzes, 7,0 Prozent bei Lippenkarzinomen und 0,0 Prozent Metastasen bei Oberlippenkarzinomen). Wurde eine alleinige Tumorresektion durchgef{\"u}hrt, traten bei 9,7 Prozent der Patienten Metastasen auf. Wurde die Behandlung durch eine pr{\"a}operative Radio-Chemo-Therapie erweitert, traten bei 35,0 Prozent der Patienten Metastasen auf. Wurde zus{\"a}tzlich noch eine postoperative Radiatio durchgef{\"u}hrt, entwickelten 38,5 Prozent der Patienten Metastasen. Nach Durchf{\"u}hrung einer alleinigen Radiatio mit 70 Gy traten bei 11,1 Prozent der Patienten Metastasen auf, nach kombinierter Radio-Chemo-Therapie (70 Gy) bei 20,5 Prozent der Patienten. Histologisch positive Resekatr{\"a}nder erh{\"o}hten die Metastasenwahrscheinlichkeit statistisch signifikant von 17,0 Prozent auf 45,7 Prozent. Von der Art der Lymphbahnausr{\"a}umung (ohne Ber{\"u}cksichtigung adjuvanter Therapien) ist die Metastasenwahrscheinlichkeit statistisch signifikant abh{\"a}ngig. Nach Durchf{\"u}hrung einer alleinigen ipsilateralen radikalen Neck dissection zeigte sich eine Metastasierungsrate von 25,6 Prozent. Wurde statt dessen eine konservierende Neck dissection durchgef{\"u}hrt, traten bei 40,0 Prozent der Patienten Metastasen auf. Wurde die ipsilaterale radikale Neck dissection mit einer kontralateralen suprahyoidalen Ausr{\"a}umung kombiniert, traten bei 37,1 Prozent der Patienten Metastasen auf. Nach ipsilateraler konservierender Neck dissection und kontralateraler suprahyoidaler Ausr{\"a}umung zeigten sich bei 55,3 Prozent der Patienten Metastasen. Die Inzidenz kontralateraler Metastasen lag bei alleiniger ipsilateraler Behandlung bei 34,3 Prozent, bei zus{\"a}tzlicher kontralateraler suprahyoidaler Ausr{\"a}umung bei 30,2 Prozent (trotz der hier zumeist vorliegenden ung{\"u}nstigeren Prognose durch gr{\"o}ßere Prim{\"a}rtumoren oder deren Lage im Bereich der K{\"o}rpermedianen).}, language = {de} } @article{MarquardtKollmannsbergerKrebsetal.2022, author = {Marquardt, Andr{\´e} and Kollmannsberger, Philip and Krebs, Markus and Argentiero, Antonella and Knott, Markus and Solimando, Antonio Giovanni and Kerscher, Alexander Georg}, title = {Visual clustering of transcriptomic data from primary and metastatic tumors — dependencies and novel pitfalls}, series = {Genes}, volume = {13}, journal = {Genes}, number = {8}, issn = {2073-4425}, doi = {10.3390/genes13081335}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-281872}, year = {2022}, abstract = {Personalized oncology is a rapidly evolving area and offers cancer patients therapy options that are more specific than ever. However, there is still a lack of understanding regarding transcriptomic similarities or differences of metastases and corresponding primary sites. Applying two unsupervised dimension reduction methods (t-Distributed Stochastic Neighbor Embedding (t-SNE) and Uniform Manifold Approximation and Projection (UMAP)) on three datasets of metastases (n = 682 samples) with three different data transformations (unprocessed, log10 as well as log10 + 1 transformed values), we visualized potential underlying clusters. Additionally, we analyzed two datasets (n = 616 samples) containing metastases and primary tumors of one entity, to point out potential familiarities. Using these methods, no tight link between the site of resection and cluster formation outcome could be demonstrated, or for datasets consisting of solely metastasis or mixed datasets. Instead, dimension reduction methods and data transformation significantly impacted visual clustering results. Our findings strongly suggest data transformation to be considered as another key element in the interpretation of visual clustering approaches along with initialization and different parameters. Furthermore, the results highlight the need for a more thorough examination of parameters used in the analysis of clusters.}, language = {en} } @article{MainzSarhanRothetal.2022, author = {Mainz, Laura and Sarhan, Mohamed A. F. E. and Roth, Sabine and Sauer, Ursula and Maurus, Katja and Hartmann, Elena M. and Seibert, Helen-Desiree and Rosenwald, Andreas and Diefenbacher, Markus E. and Rosenfeldt, Mathias T.}, title = {Autophagy blockage reduces the incidence of pancreatic ductal adenocarcinoma in the context of mutant Trp53}, series = {Frontiers in Cell and Developmental Biology}, volume = {10}, journal = {Frontiers in Cell and Developmental Biology}, issn = {2296-634X}, doi = {10.3389/fcell.2022.785252}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-266005}, year = {2022}, abstract = {Macroautophagy (hereafter referred to as autophagy) is a homeostatic process that preserves cellular integrity. In mice, autophagy regulates pancreatic ductal adenocarcinoma (PDAC) development in a manner dependent on the status of the tumor suppressor gene Trp53. Studies published so far have investigated the impact of autophagy blockage in tumors arising from Trp53-hemizygous or -homozygous tissue. In contrast, in human PDACs the tumor suppressor gene TP53 is mutated rather than allelically lost, and TP53 mutants retain pathobiological functions that differ from complete allelic loss. In order to better represent the patient situation, we have investigated PDAC development in a well-characterized genetically engineered mouse model (GEMM) of PDAC with mutant Trp53 (Trp53\(^{R172H}\)) and deletion of the essential autophagy gene Atg7. Autophagy blockage reduced PDAC incidence but had no impact on survival time in the subset of animals that formed a tumor. In the absence of Atg7, non-tumor-bearing mice reached a similar age as animals with malignant disease. However, the architecture of autophagy-deficient, tumor-free pancreata was effaced, normal acinar tissue was largely replaced with low-grade pancreatic intraepithelial neoplasias (PanINs) and insulin expressing islet β-cells were reduced. Our data add further complexity to the interplay between Atg7 inhibition and Trp53 status in tumorigenesis.}, language = {en} }